logo
Plus   Neg
Share
Email

Roche's Risdiplam Gets EMA's PRIME Designation For Spinal Muscular Atrophy

Swiss drug maker Roche Holding AG (RHHBY) announced Monday that the European Medicines Agency or EMA has granted PRIME (PRIority MEdicines) designation for the company's investigational oral medicine risdiplam (RG7916) for the treatment of people with Spinal Muscular Atrophy or SMA.

PRIME designation is granted by the EMA to support data generation and development plans for promising medicines, providing a pathway for accelerated evaluation by the agency, and thus potentially enabling them to reach patients earlier.

Risdiplam, an orally administered, survival motor neuron-2 (SMN2) gene splicing modifier, has shown improvements in motor function in people with SMA Types 1, 2 and 3.

Roche leads the clinical development of risdiplam as part of a collaboration with the SMA Foundation and PTC Therapeutics.

PRIME designation for risdiplam is based on data from Part 1 of the pivotal studies FIREFISH (evaluating safety and determining dosage in infants with Type 1 SMA) and SUNFISH (in children and adults with Type 2 and 3 SMA) as well as a continuing medical need for alternative treatments and administration options for patients with SMA.

Risdiplam is currently being investigated in three global, multicentre clinical trials in all types of SMA.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Starbucks Coffee Co. said Tuesday it is expanding its "Starbucks Delivers" pilot to an additional six cities across the U.S. The expansion of the delivery service, in partnership with Uber Eats, begins today in San Francisco, the first of six new markets to offer the service to customers. The coffee giant plans to bring Starbucks Delivers to nearly one-quarter of U.S. company-operated stores. The Port Authority of the Bay of Algeciras or APBA has signed an agreement to collaborate with Tradelens, a blockchain technology-based shipping platform, Europa News reported. Tradelens, which was launched in August last year, was jointly developed by IBM and Danish shipping giant Maersk, to bring transparency in the shipping industry. Johnson & Johnson (JNJ) Tuesday reported a profit for the fourth quarter, compared to a loss last year. The year-ago quarter's results included the impact of a hefty charge related to the U.S. tax reform. Quarterly sales increased 1.0% from the prior year. Both adjusted earnings per share and quarterly sales topped analysts' expectations.
Follow RTT